Option Care (Option Care Enterprises, Inc.), Little Rock, AR
Is Option Care (Option Care Enterprises, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Option Care (Option Care Enterprises, Inc.) hold a Arkansas pharmacy license?
State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026.
Has Option Care (Option Care Enterprises, Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Dec 20, 2019) and 1 FMD-145 letter (Dec 20, 2019) for Option Care (Option Care Enterprises, Inc.). State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Option Care Enterprises, Inc.; Option Care
- Location
- Little Rock, AR
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Dec 20, 2019
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 11 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Option Care Enterprises, Inc., (dba Option Care), a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Dec 20, 2019 | State referral letter | State Referral Letter Issued 12/20/2019 | fda.gov |
| Dec 20, 2019 | FMD-145 letter | FMD-145 Letter Issued 12/20/2019 | FDA copy (archived) |
| Mar 12, 2019 | Form 483 | 483 Issued 03/12/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Option Care Enterprises, Inc., Little Rock, AR (FEI number 3011624368), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Mar 12, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011624368 | 1082268 |
| Apr 28, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011624368 | 968814 |
Form 483s FDA has published for this site
- Mar 12, 2019: Form 483 to Option Care Enterprises, Inc., published Apr 30, 2019. fda.gov
- May 13, 2016: Form 483 to Option Care Enterprises, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 11 numbered observations in all, across 2 inspections ending Apr 28, 2016 to Mar 12, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Mar 5, 2019 to Mar 12, 2019: 3 observations
- Firm on the cover
- Option Care Enterprises Inc. dba Option Care, DRESS -9601 Baptist Health Dr ., Ste 330, Producer of sterile drugs
- FEI number
- 3011624368
- FDA district office on the cover
- 4040 North Central Expressway, Suite 300 Dallas, TX 75204
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Materials or supplies were not disinfected prior to entering the aseptic processing areas.
Specifically, on 03/05/19, l observed two operators place <Redacted B4> in ISO 5 hoods <Redacted B4>and <Redacted B4> without wiping with <Redacted B4>sterile <Redacted B4> during the production of .Milrinone 60mg, Rx <Redacted B4> and TPN 3: 1, Rx <Redacted B4> ,respectively.
Observation 2
Your facility design allowed the influx of poor quality air into a higher classified area.
Specifically, on 03/05/19, I observed the door from the non-classified area to the ISO 7 ante room open at the same time the door from the ISO 7 ante room to the ISO <Redacted B4> . This occurred during the production of Vancomycin HCL, Rx <Redacted B4> tiilrinone 60mg, Rx <Redacted B4> and TPN 3:1, Rx <Redacted B4>
Observation 3
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.
Specifically, media fills are not representative of the maximum batch size for aseptic operations for syringes and IV bags. For example, your firm produced <Redacted B4> syringes of <Redacted B4> Rx <Redacted B4> on 12/12/18, however your media fill consists of <Redacted B4>vials, <Redacted B4> syringes, and <Redacted B4>IV bag.
Inspection Apr 11, 2016 to Apr 28, 2016: 8 observations
- Firm on the cover
- , Little Rock, AR 72205-6323
- FEI number
- 3011624368
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- 4040 North Central Expressway, Suite 300, Dallas, TX 75204,
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure. Specifically, the ISO 8 Ante Room does not have a HEPA filter. Per your Clinical Pharmacy Manager the HEPA filter, REDACTED B4 and box were removed the morning of l-7-16. The room was last certified as ISO 8 on REDACTED B4. Approximately REDACTED B4 orders REDACTED B4 units) were dispensed from January 2016 to April 15, 2016.
Observation 2
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection Specifically, the following deficiencies were observed during the current inspection ...
Observation 3
Procedures designed to prevent microbiological contamination ofdrug produels purporting to be sterile are not followed.
Specifically,
1. Improper donning of sterile gloves in which the operator touched the critical surface of the glove with their bare hand. This practice was observed repeatedly during production of RX REDACTED B6 TPN REDACTED B4 on 4/11/16. In addition, operators were observed moving between the ISO 7 Buffer Room and e ISO 8 Ante Room without sanitizing or changing their sterile gloves prior to placing them back inside of the ISO 5 zone during compounding of RX REDACTED B6 TPN REDACTED B4 on 4-1 1-16 and during cleaning of the ISO 5 zones on 4-12-16. 1. Improper donning of sterile gloves in which the operator touched the critical surface of the glove with their bare hand. This practice was observed repeatedly during production of RX REDACTED B6 TPN REDACTED B4 on 4/11/16. ...
Observation 4
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
Your firm does not perform viable and non-viable environmental monitoring each day that sterile drug products are produced. Your pharmacy director stated viable air sampling is REDACTED B4 performed, but you do not document the location or results. Furthermore, SOP Pharmacy 4.4 states “***Air sampling must not be performed REDACTED B4 ***”. 2. Your firm does not perform gloved finger-tip testing each day drugs purporting to be sterile are produced. Your Inventory Specialist operators are tested REDACTED B4 without use of positive and negative controls. Furthermore, your firm uses REDACTED B4 plates incubated for REDACTED B4 hours at REDACTED B4, however, the package insert states the agar should be incubated for REDACTED B4 hours at REDACTED B4 then read. 2. Your firm does not perform glove finger-tip testing each day drugs purporting to be sterile are produced. Your Inventory Specialist stated operators are tested REDACTED B4 without use of positive and negative controls. ...
Observation 5
Test procedures relative to appropriate laboratory testing for sterility are not followed.
Specifically, your firm failed to follow the instructions for use of the REDACTED B4 used to REDACTED B4 test the sterility of TPN. The instructions state to incubate a REDACTED B4 however, your firm incubators are set at REDACTED B4 and your inventory specialist stated you incubate at REDACTED B4 for REDACTED B4. Your firm has tested approximately REDACTED B4 TPNs from January 2015 to April 2016.
) ...:.-:-')'---:_--::o_ Specifically, your firm failed to follow the instructions for use of the REDACTED B4 used to REDACTED B4 test the sterility of TPN. The instructions state to incubate a REDACTED B4 however, your firm incubators are set at REDACTED B4 and your inventory specialist stated you incubate at REDACTED B4 for REDACTED B4. Your firm has tested approximately REDACTED B4 TPNs from January 2015 to April 2016.
Observation 6
Investigations of an unexplained discrepancy and a failure of a batch or any of its components to meet any of its specifications did not extend to other drug products that may have been associated with the specific failure or discrepancy.
Specifically, your firm does not thoroughly investigate patient complaints and deviations from your production of sterile products. For example,
1. Incident report dated 3/3/16 states the pharmacist used NaCI REDACTED B4, Iot REDACTED B4 expiry date 12/2015 while producing NaCI 0.9% with electrolytes I000mL on 2/18/16 and subsequently dispensed on 2/18/16. No investigation was conducted to determine if the expired lot was used to produce additional sterile drug products. 1. Incident report dated 3/3/16 states the pharmacist used NaCI REDACTED B4, Iot REDACTED B4 expiry date 12/2015 while producing NaCI 0.9% with electrolytes I000mL on 2/18/16 and subsequently dispensed on 2/18/16. No investigation was conducted to determine if the expired lot was used to produce additional sterile drug products.
2. ...
Observation 7
Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform. Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform. Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform. Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform. Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform. Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform. Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform. Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform. ...
Observation 8
Routine calibration of automatic and electronic equipment is not performed according to a written program designed to assure proper performance. Specifically, your Clinical Pharmacy Manager stated the REDACTED B4 pressure gauges were installed approximately 2-3 years ago to monitor pressure differential between the REDACTED B4 room and REDACTED B4 room and REDACTED B4 room to general pharmacy area, but were not calibrated every REDACTED B4 as indicated by the manufacturing instructions. The first calibration of the pressure gauges was REDACTED B4 and no COA was provided to certify calibration was NIST standards.
Furthermore, your firm did not have a pressure gauge measuring the pressure differential from the REDACTED B4 room to the general pharmacy area until September 2015. In addition, no pressure differentials were documented for the month of August 2015 in which approx. the REDACTED B4 orders were compounded.
State board of pharmacy records
State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
- Option Care, Wood Dale, IL
- Option Care Enterprises, Columbia, MD
- Option Care Enterprises Inc, Everett, WA
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.